title: Identification of quinazoline compounds as novel potent inhibitors of Wnt/β-catenin signaling in colorectal cancer cells.
abstract: The Wnt/β-catenin signaling pathway is critical for the initiation and progression of most colon cancers, and has emerged as one of the most promising targets for colorectal cancer chemoprevention and treatment. In this study, we have discovered a structurally related series of quinazolines as potent inhibitors of Wnt/β-catenin signaling in colorectal cancer cells harboring mutations in CTNNB1 or APC. We showed that the quinazoline leads suppressed Wnt/β-catenin signaling without altering the level of β-catenin protein in colorectal cancer cells, suggesting that they act on the downstream elements of the pathway. Moreover, the quinazoline leads displayed potent anticancer activities with IC50 values between 4.9 and 17.4 μM in colorectal cancer cells. Importantly, we also found that a structurally related quinazoline lacking inhibitory effect on Wnt/β-catenin signaling was unable to suppress colorectal cancer cell proliferation. Together, these results suggest that the quinazoline lead compounds identified in this study have therapeutic potential for the prevention and treatment of colorectal cancer.
authors.affiliation: Drug Discovery Division, Southern Research Institute, Birmingham, AL 35205, United States of America.
authors.forename: Yonghe
authors.initials: Y
authors.lastname: Li
authors.affiliation: Drug Discovery Division, Southern Research Institute, Birmingham, AL 35205, United States of America.
authors.forename: Wenyan
authors.initials: W
authors.lastname: Lu
authors.affiliation: Drug Discovery Division, Southern Research Institute, Birmingham, AL 35205, United States of America.
authors.forename: Surendra K
authors.initials: SK
authors.lastname: Saini
authors.affiliation: Drug Discovery Division, Southern Research Institute, Birmingham, AL 35205, United States of America.
authors.forename: Omar
authors.initials: O
authors.lastname: Moukha-Chafiq
authors.affiliation: Drug Discovery Division, Southern Research Institute, Birmingham, AL 35205, United States of America.
authors.forename: Vibha
authors.initials: V
authors.lastname: Pathak
authors.affiliation: Drug Discovery Division, Southern Research Institute, Birmingham, AL 35205, United States of America.
authors.forename: Subramaniam
authors.initials: S
authors.lastname: Ananthan
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000378:metabolism*; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D020128:Inhibitory Concentration 50; D011799:Quinazolines / Q000494:pharmacology*; D060449:Wnt Signaling Pathway / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines
keywords: Wnt inhibitor; Wnt signaling; colorectal cancer; drug discovery; quinazoline
references.citation: Bioorg Med Chem. 2010 Jun 1;18(11):3812-22
references.pmid: 20466555
references.citation: Mol Cell Biol. 2002 Feb;22(4):1172-83
references.pmid: 11809808
references.citation: Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14973-8
references.pmid: 11752446
references.citation: J Med Chem. 2012 Feb 9;55(3):1346-59
references.pmid: 22229647
references.citation: Eur J Med Chem. 2015 May 5;95:526-45
references.pmid: 25847770
references.citation: Proc Natl Acad Sci U S A. 1999 May 11;96(10):5522-7
references.pmid: 10318916
references.citation: EMBO J. 2012 Jun 13;31(12):2737-46
references.pmid: 22617421
references.citation: J Biol Chem. 2002 Jun 14;277(24):21657-65
references.pmid: 11940574
references.citation: Cell. 2015 Jun 18;161(7):1539-52
references.pmid: 26091037
references.citation: J Med Chem. 2010 Jan 28;53(2):897-910
references.pmid: 20025292
references.citation: Nature. 1999 Apr 1;398(6726):422-6
references.pmid: 10201372
references.citation: Bioorg Med Chem Lett. 2009 Sep 1;19(17):4980-3
references.pmid: 19640711
references.citation: Science. 1997 Mar 21;275(5307):1787-90
references.pmid: 9065402
references.citation: Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):5929-30
references.pmid: 21451134
references.citation: Nat Rev Drug Discov. 2014 Jul;13(7):513-32
references.pmid: 24981364
references.citation: Nat Rev Cancer. 2013 Jan;13(1):11-26
references.pmid: 23258168
references.citation: Bioorg Med Chem Lett. 2006 Sep 1;16(17):4686-91
references.pmid: 16777410
references.citation: Clin Cancer Res. 2011 Feb 15;17(4):647-53
references.pmid: 21159886
references.citation: Cell. 1996 Oct 18;87(2):159-70
references.pmid: 8861899
references.citation: FEBS Lett. 2008 Mar 5;582(5):643-50
references.pmid: 18242177
references.citation: Oncotarget. 2014 Feb 28;5(4):978-92
references.pmid: 24657851
references.citation: Mol Cancer Ther. 2015 May;14(5):1087-94
references.pmid: 25901018
references.citation: PLoS One. 2011;6(12 ):e29290
references.pmid: 22195040
references.citation: J Med Chem. 2010 Feb 25;53(4):1413-37
references.pmid: 20166671
references.citation: Oncogene. 2005 May 19;24(22):3619-31
references.pmid: 15782138
references.citation: Oncogene. 1998 May 28;16(21):2819-25
references.pmid: 9652750
references.citation: Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):5954-63
references.pmid: 21393571
references.citation: Lancet. 2003 Jul 19;362(9379):205-9
references.pmid: 12885482
references.citation: Bioorg Med Chem Lett. 2001 Jul 23;11(14):1911-4
references.pmid: 11459659
references.citation: Exp Cell Res. 2011 Nov 15;317(19):2748-58
references.pmid: 21884696
references.citation: Mol Cell Biol. 2002 Feb;22(4):1184-93
references.pmid: 11809809
references.citation: Cell. 2012 Jun 8;149(6):1192-205
references.pmid: 22682243
references.citation: Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12649-54
references.pmid: 23847203
references.citation: Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9
references.pmid: 24277854